QuidelOrtho Corporation Overview
Pro stress-test →QuidelOrtho Corporation is a global leader of innovative in vitro diagnostics that operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. In 2025, the company transitioned from COVID-driven volatility to a more durable, diversified diagnostics business.
Strategic Profile
Pro stress-test →Labs, Immunohematology and Cardiac businesses delivered consistent growth, while cost-savings initiatives drove meaningful margin expansion, positioning the company to generate substantially stronger free cash flow in 2026. The company is shifting strategic focus to Labs and non-respiratory growth areas, while acknowledging expected declines, particularly with donor screening winding down by mid-2026.
Competitive Landscape
Pro stress-test →QuidelOrtho competes in in vitro diagnostics across multiple channels including direct sales and distributor networks to physician offices, hospitals, clinical laboratories, and other healthcare settings. Primary competitors include Siemens Healthineers, Abbott Diagnostics, Roche Diagnostics, Bio-Rad Laboratories, and Ortho Clinical Diagnostics in transfusion medicine and broader diagnostic testing segments.
Industry Context
QuidelOrtho Corporation operates in Healthcare Diagnostics / In Vitro Diagnostics (IVD).
Key facts
Founded: 1979 · Headquarters: San Diego, United States · Revenue: $2.73B